In Vitro Induction Studies: Elements of Design and Important Considerations in Data Analysis
Presenter: Joanna Barbara, Ph.D., Vice President of Scientific Operations at XenoTech
Synopsis: When evaluating drug-drug interaction (DDI) risk of an investigational drug, a battery of studies is needed to investigate victim/perpetrator potential. One of these comprises evaluation of the potential of a new therapy to induce drug-metabolizing enzymes, which can impact clearance of concomitantly administered drugs. The team at XenoTech has built a reputation of dedicating high quality resources and specialists to conduct such studies with scientific rigor.
In this webinar, Dr. Joanna Barbara will address frequently asked questions from sponsors seeking induction studies and elaborate on some recommendations we give to achieve successful regulatory submission. Points of discussions will include an overview of enzyme induction studies and critical considerations in design, from determination of supporting data to conclusive interpretation.
Key concepts discussed in this webinar will include:
- Standard study considerations
- FDA guidance requirements
- Required endpoints for IND submission
- 3A induction and associated challenges
- Next-step recommendations
What topic would you like to hear about?
Our experts are constantly on the hunt for new and exciting topics to present on, and nothing helps us figure out what you want to hear more than requests and feedback! Use our form to submit your request so we can continue producing educational materials you look forward to
